USPTO serial 85193730
SYMPHOMAX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- BOONE, JOHN C
- Law office
- TMEG LAW OFFICE 104 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with SYMPHOMAX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kaushal R. Odedra
KAUSHAL R. ODEDRA ODEDRA LAW OFFICE, PLLC2020 PENNSYLVANIA AVE NW # 152WASHINGTON, DC 20006-1811UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Host cells for medical or clinical use; cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; pharmaceuticals, namely, central nervous system depressants, preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating agents, diuretics, hypotensors, prophylactic for the treatment of asthma, antitussives and expectorants, stomachics and digestives, antacids, hormones, namely, pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis, corticosteroids for treatment of hypopituitarism, congenital adrenal hyperplasia, rheumatoid arthritis, rheumatic fever, crohn's disease, and chronic active hepatitis, estrogen and progesterone used as combined oral contraceptives, urinary antiseptics, analgesics, anti-itching agents, cataplasms for the treatment of bruises, lumbago and stiff shoulder, pharmaceutical preparations used to treat hair disorders, vitamin preparations, food enriching agents for treating vitamin deficiencies, anti-coagulants, enzyme preparations for control of malabsorption and diarrhea, anti-cancer preparations, anti-sarcoma preparations, antibiotics and their preparations for the treatment of infectious diseases, antituberculotic agents, influenza vaccines, diphtheria vaccines, tetanus vaccines, gas gangrene vaccines, Japanese encephalitis vaccines, in vitro tetrodotoxines for medical use, antiprotozoals for the treatment of trichomoniasis and dermatophytosis, anthelmintics for the treatment of threadworm and toxoplasmaosis, naturally occurring drugs for treating peptic ulcers, charred drugs for treating peptic ulcers, moxa for treating peptic ulcers, veterinary drugs for the treatment of distemper in dogs, distomatosis in dogs, coccidian in chickens, and dysentery in pigs, germination controllers and plant rearing agents, namely, herbicides, fungicides, insecticides, bactericides and rodenticides for domestic and or agricultural use, antiseptics, drugs for arteriosclerosis, oncostatic drugs for the treatment for cancer, multienzyme digestants for in vivo use; antifungal antibiotics for treating trichomoniasis and dermatophytosis, anti parkinsonism drugs, minor tranquilizers, and anti anxiety agents, medicinal preparations for the treatment of the central nervous system, the respiratory tract and the cardiovascular system, anti-bacterial preparations, monolithic preparations, medicinal preparations for the treatment of peptic ulcers, anti-inflammatory preparations, analgesic preparations, cephalosporin, cocarboxylase preparations, glutathione preparations, preparations for improving the metabolism and the peripheral circulation, plasma substitutes and extracorporeal circulation flow improvement preparations, diuretic and anti-hypertensive preparations, in vitro diagnostic reagents for medical use, in vitro extra corporeal diagnostic reagents for medical use, in vitro x-ray contrast agents for medical use, in vitro diagnostic media, pharmaceutical preparations for the treatment of insomnia and other sleep related diseases | ACTIVE | — |
| 040 | Contract manufacturing service in the field of antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of host cells; contract extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals; providing information in the field of manufacturing technology in the field of antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of manufacturing technology in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of manufacturing technology in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of manufacturing technology in the field of host cells; technical consultation in the field of manufacturing technology in the field of host cells; providing technical information in the field of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals technical consultation in the field of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals | ACTIVE | — |
| 042 | Development of new products for others in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells; providing technical information in the field of development of new products in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells; technical consultation in the field of development of new products in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 22, 2013 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Mar 22, 2013 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Aug 24, 2012 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 24, 2012 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 9, 2012 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 8, 2012 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 10, 2012 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 9, 2012 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 9, 2012 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 27, 2011 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 24, 2011 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 23, 2011 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 22, 2011 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 22, 2011 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Nov 22, 2011 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Nov 16, 2011 | CNSL | LETTER OF SUSPENSION MAILED | — |
| Nov 15, 2011 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Oct 7, 2011 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 7, 2011 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 29, 2011 | ALIE | ASSIGNED TO LIE | — |
| Sep 20, 2011 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 21, 2011 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 21, 2011 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 12, 2011 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 14, 2010 | MPMK | NOTICE OF PSEUDO MARK MAILED | — |
| Dec 13, 2010 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 11, 2010 | NWAP | NEW APPLICATION ENTERED | — |